Embecta Corp. (EMBC)
Summary
Embecta Corp. (EMBC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Embecta Corp. (EMBC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Embecta Corp. (EMBC) Q2 2026 Earnings Call Transcript
Embecta Corp. (EMBC) Q2 2026 Earnings Call Transcript
Embecta Corp. (EMBC) Q1 2026 Earnings Call Transcript
Embecta Corp. (EMBC) Q1 2026 Earnings Call Transcript
Embecta Corp. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 105 | $2,542.17 | $331.16 | -$2,211.01 | -86.97% |
| CE Curtis Ellergodt Rothschild Investment LLC | 180 | $2,271.37 | $567.7 | -$1,703.67 | -75.01% |
 Tweedy Browne Tweedy, Browne Company LLC | 75,356 | $815,880.53 | $237,748.18 | -$578,132.35 | -70.86% |
 Donald Yacktman Yacktman Asset Management | 3.67M | $66.36M | $11.55M | -$54.81M | -82.6% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 1,281 | $17,419.94 | $4,028.74 | -$13,391.2 | -76.87% |
Embecta Corp. (EMBC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Embecta Corp. ever had a stock split?
Embecta Corp. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Devdatt Kurdikar CEO | NASDAQ (NGS) Exchange | 29082K105 CUSIP |
| US Country | 2,000 Employees | 28 May 2026 Last Dividend | - Last Split | 1 Apr 2022 IPO Date |
Overview
Embecta Corp. stands as a pioneering medical device company with its focus sharply attuned to enhancing the health and wellbeing of individuals battling diabetes. With its roots planted as far back as 1924, Embecta has burgeoned into a flagship enterprise, dedicated to delivering innovative solutions for diabetes management. Operating from its headquarters in Parsippany, New Jersey, the company has marked its presence both in the United States and on an international spectrum, predominantly through wholesalers and distributors. The essence of Embecta's mission revolves around its commitment to supporting people with diabetes through its extensive range of products and digital applications designed for efficacious diabetes management.
Products and Services
- Pen Needles
- Syringes
- Safety Injection Devices
- Digital Applications
Pen needles from Embecta are tailored for ease of use and comfort, meeting the diverse needs of individuals requiring insulin or other injectable diabetes medications. These needles are designed to facilitate a less painful insertion process, enhancing the overall experience of daily diabetes management.
Embecta presents a range of syringes geared towards ensuring accuracy, safety, and comfort during insulin delivery. These syringes are constructed with patient safety in mind, incorporating features that aim to minimize injection-related anxiety and complications.
The company's Safety Injection Devices are developed with cutting-edge technology to mitigate the risks associated with needlestick injuries, a concern for both healthcare providers and patients. These devices embody the essence of Embecta's commitment to safety in diabetes care.
Recognizing the growing need for digital health solutions, Embecta has ventured into providing digital applications designed to assist individuals in managing their diabetes more effectively. These applications offer tools for monitoring blood sugar levels, medication tracking, and personalized insights into one’s diabetes management plan, ultimately aiming to empower users with control over their health.
